
    
      The physician will be requested:

        -  To include 15 consecutive patients aged > or = 65 years who will be treated with
           anthracyclines in first and second line MBC. The physician will be encouraged to enrol 2
           arms of 8 patients (one treated with liposomal and one with non-liposomal
           anthracyclines) for observation and comparison. Each arm will be closed as soon as 150
           patients are included at a national level.

        -  To report their cardiovascular risk factors

        -  To provide the results of routinely performed cardiac evaluation before treatment

        -  To monitor routinely cardiovascular parameters during treatment and report them
           afterwards

        -  To monitor efficacy and tolerance of treatments, as normal practice prescribes, reported
           and related to the variables described in objectives

        -  To ensure that quality of life will be assessed with the EORTC QLQ-C30 questionnaire

        -  To monitor and report progression free survival and cardiac events

        -  To record and transmit spontaneously reported adverse events. These will be handled
           according to legal requirements

      Follow-up will cover a period of 15 months following inclusion.

      The study will have 3 visits and 2 contacts:

        -  One visit at entry

        -  One visit after 3 cycles of anthracycline containing therapy

        -  One visit at the end of treatment

        -  Contact at 9 months after inclusion

        -  Contact at 15 months after inclusion

      It is planned to include data from 15 consecutive female patients per specialized center in
      Belgium.

      The total number of patients aimed is 300.
    
  